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Abstract
Background: Atherosclerosis is a complex pathological condition caused by a number of mechanisms including the accelerated
proliferation of vascular smooth muscle cells (VSMCs). Diabetes is likely to be an important risk factor for atherosclerosis, as
hyperglycemia induces vascularsmooth muscle cell(VSMC) proliferation andmigrationand may thus contributeto theformation
of atherosclerotic lesions. This study was performed to investigate whether PGC-1a,aP P A R c coactivator and metabolic master
regulator, plays a role in regulating VSMC proliferation and migration induced by high glucose.
Methodology/Principal Findings: PGC-1a mRNA levels are decreased in blood vessel media of STZ-treated diabetic rats. In
cultured rat VSMCs, high glucose dose-dependently inhibits PGC-1a mRNA expression. Overexpression of PGC-1a either by
infection with adenovirus, or by stimulation with palmitic acid, significantly reduces high glucose-induced VSMC
proliferation and migration. In contrast, suppression of PGC-1a by siRNA mimics the effects of glucose on VSMCs. Finally,
mechanistic studies suggest that PGC-1a-mediated inhibition of VSMC proliferation and migration is regulated through
preventing ERK1/2 phosphorylation.
Conclusions/Significance: These results indicate that PGC-1a is a key regulator of high glucose-induced proliferation and
migration in VSMCs, and suggest that elevation of PGC-1a in VSMC could be a useful strategy in preventing the
development of diabetic atherosclerosis.
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Introduction
Atherosclerosis and microvascular diseases are the major
vascular complications of diabetes, and constitute the principal
causes of morbidity and mortality among diabetics [1,2]. While
many factors potentially contribute to the development of diabetic
atherosclerosis including abnormalities in plasma lipoproteins and
blood pressure, hyperglycemia is generally believed to be a major
causative factor [3]. Chronic hyperglycemia-induced atheroscle-
rosis involves a complex series of events, including abnormal
vascular smooth muscle cell (VSMC) proliferation and migration,
which contribute importantly to the formation of organized
atherosclerotic plaque. High glucose activates the expression of
several genes involved in extracellular signal-regulated kinase
(ERK)-dependent mitogenic response, contributing to VSMC
proliferation and migration and, as a result, to the development of
atherosclerosis [4–6].
Recent studies demonstrated that TZDs, the PPARc ligands,
decreased cardiovascular risks via exerting direct effects on
vascular cells, for example, inhibition of VSMC proliferation
and migration [7,8]. It has been shown that TZDs inhibit key steps
in the ERK/MAPK pathway, blocking events that are critical for
the re-entry of quiescent VSMCs into cell cycle, thus retarding
serum-induced growth of cultured arterial VSMCs and PDGF-
BB–directed migration of VSMCs [9–12]. Direct vascular effects
of TZDs result from their activity as ligands for the nuclear
receptor, PPARc [7].
PGC-1a is a transcriptional coactivator of PPARc and regulates
expression of many genes coding for mitochondrial proteins [13–
15]. PGC-1a plays important roles in many physiological
processes, including adipocyte cell differentiation [13], the
regulation of adaptive thermogenesis in brown fat and muscle
[13,16], control of hepatic gluconeogenesis [17], fuel selection in
skeletal muscle cells [18], and suppression of reactive oxygen
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PGC-1a expression changes in tissues depending on glucose levels,
as seen in diabetic subjects [17,20–23], thus mediating effects of
hyperglycemia and promoting pathological conditions. For
example, PGC-1a is upregulated in liver of rodents in models of
both type 1 and type 2 diabetes, and increased PGC-1a expression
contributes to elevated hepatic glucose output and the develop-
ment of hyperglycemia [17]. Here, we sought to establish whether
hyperglycemia regulates PGC-1a levels in VSMCs and whether
such changes are causally related to hyperglycemia-induced
VSMC proliferation and migration. Our results suggest that
PGC-1a is a glucose-responsive, negative regulator of VSMC
proliferation and migration.
Results
High Glucose-induced VSMC proliferation and migration
is associated with decreased PGC-1a expression
High glucose has been reported to increase rat VSMC growth
and movement [3,6]. To confirm the previous report, cultured rat
VSMCs were incubated with various concentrations of glucose.
Following 48 h incubation, glucose dose-dependently induced
VSMC proliferation (Fig. 1A) and migration (Fig. 1B). 11 mmol/L
glucose induce VSMC proliferation by 1.2-fold and VSMC
migration by 3-fold, respectively. At 15 mmol/L glucose numbers
of VSMC were nearly 1.5-fold higher than that of control group,
while migration distance was increased by 4-fold compared to the
control group. 25 mmol/L glucose further stimulated cell growth
by 1.6-fold and cell migration by 6-fold.
The glucose-induced VSMC proliferation and migration was
found to be associated with the inhibition of the expression of
PGC-1a. As shown in Fig. 1C, 11 mmol/L glucose inhibited
PGC-1a mRNA expression in rat VSMCs to 52624% relative to
the 5.5 mmol/L control, at 15 mmol/L glucose PGC-1a mRNA
expression was 3162% of control, and 25 mmol/L glucose (the
highest glucose condition) reduced the PGC-1a mRNA expression
to 2067% of control.
We also examined PGC-1a mRNA expression in the blood
vessel media (VSMC is the only cell type in this layer) in normal
and STZ injected rat arterial samples. In STZ-treated rats, PGC-
1a mRNA level was decreased by 66614% compared to the
control group (Fig. 1D).
Overexpression of PGC-1a suppresses high glucose
induced VSMC proliferation and migration
To further study the role of PGC-1a in VSMC proliferation and
migration, VSMCs were infected with adenovirus driving the
overexpression of PGC-1a. After 24 h PGC-1a mRNA and
protein level was markedly elevated. As shown in Fig. 2A and 2B,
after infection with Ad-PGC-1a, the PGC-1a mRNA level in
VSMCs was approximately 60-fold higher than negative control
group (Ad-GFP) (Fig. 2A), and PGC-1a protein level also
increased significantly (Fig. 2B). Subsequently added high glucose
did not affect this elevation (data not shown).
15 mmol/L glucose was used to stimulate VSMC growth and
movement, the number of Ad-GFP infected cells, cultured in
15 mmol/L glucose were nearly 1.5-fold higher than cells cultured
at 5.5 mmol/L glucose (1.4160.07610
6 cell/dish versus
Figure 1. High Glucose-induced VSMC proliferation and
migration is associated with decreased PGC-1a expression.
Cultured rat VSMCs were incubated for 48 h in 5.5 mM, 11 mM, 15 mM
and 25 mM glucose respectively, Cell growth was determined by
counting the number of cells (A) and VSMC migration was determined
by a standard wound healing assay (B), PGC-1a expression was
determined by real-time RT-PCR by using primers specific for rat PGC-1a
and b-actin (C). The bars represent means6S.E.M (n=6). *P,0.05,
**P,0.01, #P,0.001 vs. cells incubated in 5.5 mM glucose. Arterial
samples were obtained from the normal and STZ injected rats, the
intima and outer and inner tissue layers were removed from arteries.
PGC-1a expression was determined by real-time RT-PCR. Data (n=10)
were expressed as means6S.E.M. *P,0.05 vs. normal rats (D).
doi:10.1371/journal.pone.0004182.g001
Figure 2. Overexpression of PGC-1a suppresses high glucose
induced VSMC proliferation and migration. Cultured rat VSMCs in
5.5 mM glucose infected with adenovirus driving the expression of
PGC-1a (PGC group) or GFP (GFP group) were either left untreated or
incubated with 15 mM gluoose (HG) for 48 h. PGC-1a mRNA expression
was determined by real-time RT-PCR (A), the values of PGC-1a/b-actin
were normalized to that of control. 60 mg total proteins from VSMCs
were assayed for Westernblot with PGC-1 antibody (B). Cell growth was
determined by counting the number of cells (C). VSMC migration was
determined by a standard wound healing assay (D) and by transwell
analysis (E). The bars represent means6S.E.M (n=6). **P,0.01,
#P,0.001 compared with the GFP control group (GFP group).
doi:10.1371/journal.pone.0004182.g002
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6,P ,0.001, n=6, Fig. 2C). High glucose also
significantly stimulated cell migration in Ad-GFP infected group,
as determined by wound healing assay (37.3368 versus
114.67625.33 mm, P,0.001, n=6, Fig. 2D) and transwell
chamber assay (662.9 versus 101615.7; P,0.001, Fig. 2E).
Strikingly, when cells were infected with Ad-PGC-1a, the ability of
high glucose to induce VSMC proliferation was entirely lost
(1.0160.06610
6 versus 1.0560.06610
6 cells/dish, P.0.05, n=6,
Fig. 2C). The wound healing assay showed that high glucose-
induced VSMC migration was significantly decreased after
overexpression of PGC-1a compared to control cells cultured at
high glucose (35.55611.10 versus 114.67625.33 mm, P,0.001,
n=6, Fig. 2D). A similar result was seen in the transwell chamber
assay, where the number of migrated cells in high glucose was 461
following overexpression of PGC-1a compared to 101615.7 in the
Ad-GFP infected cells (also at 15 mmol/L glucose) (Fig. 2E). Note
that, under high glucose conditions, cells overexpressing PGC-1a
essentially showed the same migration distance and number of
migrated cells as the control cells (GFP group without high glucose
stimulation). In summary, using multiple assay formats, overex-
pression of PGC-1a clearly suppresses high glucose-induced
VSMC proliferation and migration.
Knock-down of PGC-1a by siRNA accelerates high
glucose-induced VSMC proliferation and migration
To further test the effect of PGC-1a on VSMC proliferation
and migration, we knocked down PGC-1a expression in VSMCs
by siRNA interference. As shown in Fig. 3A and 3B, our siRNA
inhibited PGC-1a expression to about 30%. In contrast to the
inhibitory effect of elevated PGC-1a on VSMC growth, decreased
PGC-1a level accelerated high glucose-induced VSMC prolifer-
ation and migration. Under high glucose conditions (15 mmol/L
as in the previous experiments), knocking down PGC-1a increased
VSMC number compared to control (1.9960.37610
6 versus
1.3260.15610
6 cells/dish, P,0.05, n=6, Fig. 3C). In addition,
following PGC-1a knock-down, VSMC migration distance was
further induced under high glucose conditions when compared to
the negative control group (N) (176.25617.81 mm versus
126.25623.82, P,0.05, n=6, Fig. 3D). Finally, transwell analysis
confirmed that PGC-1a knock-down increased the number of
migrated VSMCs compared to control (190.2069.78 versus
109.4614.40, P,0.001, Fig. 3E).
Palmitic acid stimulates PGC-1a expression and inhibits
high glucose-induced VSMC growth and movement
In a previous study, we had shown that palmitic acid stimulates
endogenous PGC-1a expression in VSMCs [24]. Therefore, we
used palmitic acid in these experiments as yet another way of
modulating PGC-1a and assessing the effects on cell growth and
proliferation. 0.4 mmol/L palmitic acid alone increased PGC-1a
mRNA level 2.7-fold after 48 h incubation, the protein level also
increased after treatment with 0.4 mmol/L palmitic acid (Fig. 4A
and 4B). The effect of palmitic acid on PGC-1a expression was not
reversible by glucose, as shown by concomitant incubation of
VSMCs with 15 mmol/L glucose and 0.4 mmol/L palmitic acid
(Fig. 4A and 4B).
Relative to control, palmitic acid alone had no effect on VSMC
proliferation (Fig. 4C) and migration(Fig. 4D and 4E), however
VSMC proliferation and migration were kept to the level of the
control when cells were incubated with high glucose plus palmitic
acid. As shown in Fig. 4C, incubation of VSMCs with 0.4 mmol/
L palmitic acid in the presence of 15 mmol/L glucose ablated the
effect of high glucose on cell growth. (0.9260.07610
6 versus
1.3860.05610
6 cell/dish, P,0.001, n=6, Fig. 4C). Data
presented in Fig. 4D show that directional migration of VSMCs
stimulated by high glucose were inhibited by palmitic acid
(111.11632.29 versus 32.10615.42 mm, P,0.001, n=6,
Fig. 4D), and transwell analysis confirmed that the number of
migrated cells was fewer in the PA+HG group than in the HG
group (37618.6 versus 107614.0, P,0.001, n=6, Fig. 4F).
To further investigate whether the inhibitory effects of palmitic
acid on high glucose-induced VSMC proliferation and migration
result from its capacity to elevate PGC-1a expression, we
transfected VSMCs with siRNA to knock down PGC-1a, and
then submitted the cells to the high glucose conditions while in
presence of palmitic acid in the medium. We confirmed the
interference efficiency and found that PGC-1a expression was
decreased by 60–70% at both the mRNA and protein levels (data
not shown). Following PGC-1a knockdown, the inhibitory effect of
palmitic acid on VSMC proliferation and migration was
abolished. As shown in Fig. 5A, in the presence of palmitic acid
and high glucose, the number of cells in the siRNA-transfected
cells was 1.3-fold higher than the negative control group
(1.0760.10610
6 versus 0.8560.07610
6 cell/dish, P,0.05,
n=6, Fig. 5A). In the presence of high glucose and palmitic acid,
migration distance was 81611 mm following PGC-1a knock-
Figure 3. Knock-down of PGC-1a accelerated high glucose-
induced VSMC proliferation and migration. VSMCs transfected
with siRNA (SI) or the negative control (N), were either left untreated or
stimulated with 15 mM gluoose (HG). The interference effect was
assessed by quantitative PCR analysis and data were shown as the ratio
of PGC-1a/b-actin (A), **P,0.01compared with the negative control
group (N). 120 mg total proteins from VSMCs were assayed for Western
blot with PGC-1 antibody to confirm the interference effiency (B).
Effects of decreased PGC-1a on high glucose-induced VSMC prolifer-
ation were determined by cell counting (C). VSMC migration was
determined by wound healing (D) and transwell analysis (E). Individual
data points in this figure represents the mean6S.E.M (n=6). *P,0.05,
#P,0.001 compared with the control group (N+HG).
doi:10.1371/journal.pone.0004182.g003
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mirrored in the transwell assay (11363 versus 23.867 cells,
P,0.001, n=6, Fig. 5C). These results indicate that even in the
presence of palmitic acid (a strong stimulant of PGC-1a
expression), PGC-1a knockdown induces VSMC proliferation
and migration, essentially to a level comparable to high glucose
alone. Thus, PGC-1a is likely an integration point in VSMCs for
nutrient signals, which are likely to engage different signaling
pathways upstream of PGC-1a.
PGC-1a inhibits activation of the ERK1/2 pathway in
VSMCs by high glucose
High glucose stimulates VSMC proliferation and migration
through the activation of MAPK ERK signaling [3,4]. Consistent
with these reports, our results show that high glucose activated
ERK1/2, a key element of the ERK MAPK pathway. Following
PGC-1a overexpression, the ERK1/2 protein in VSMC no longer
was activated by high glucose (see Fig. 6A), the phosphorylation of
ERK in VSMCs transfected with Ad-PGC-1a decreased approx-
imately 78% compared with that in Ad-GFP infected group under
high glucose conditions. Furthermore, palmitic acid, which has
been shown to stimulate PGC-1a expression, seemed to have little
effect on ERK phosphorylation, but high glucose-induced
phosphorylation of ERK almost reverted to the level of control
by the addition of palmitic acid (see Fig. 6B). These results suggest
that PGC-1a inhibits VSMC proliferation and migration through
the inhibition of MAPK ERK pathway.
Discussion
PGC-1a, an important transcriptional coactivator, plays a key
role in energy metabolism [14,15]. PGC-1a expression is highly
related to glucose metabolism, and its expression level changes in
various tissues in rodent models of diabetes. It has previously been
shown that both mRNA and protein levels of PGC-1a were
significantly reduced in adipose tissue from insulin-resistant subjects
[23]. Similarly, decreases in the mRNA levels of PGC-1a were
found in skeletal muscle from type 2 diabetics [21]. In contrast,
PGC-1a mRNA levels are elevated in the liver [17,20], as well as in
hearts of rodents in models of both type 1 and type 2 diabetes [22].
These changes in PGC-1a levels served as a causal factor or as a
mediator of the corresponding pathophysiologic processes. In
addition to alterations of the insulin/glucagon axis, the direct effect
of chronic hyperglycemia may affect the expression level of PGC-
1a. In our previous study, we were the first to report that high
glucose directly inhibits PGC-1a expression in isolated rat islets
[25]. Here, we show that PGC-1a mRNA expression is inhibited in
blood vessel media in STZ-diabetic rats. Further experiments
revealed that high glucose directly, and dose-dependently, inhibits
PGC-1a mRNA expression in cultured rat VSMCs (Fig. 1). These
results indicate that high glucose decreases PGC-1a expression in
VSMCs both in vivo and in vitro. However, the precise mechanism
through which high glucose regulates PGC-1a expression in VSMC
needs further study.
A large body of work has established that chronic hyperglyce-
mia promotes VSMC proliferation and migration and contributes
to the progress of diabetic atherosclerosis [1–3]. Previous studies
show that the PPAR family of proteins may be involved in the
process [7]. TZD inhibits VSMC proliferation and migration
through the activation of PPARc, which tends to inhibit the
expression of several genes involved in ERK-dependent mitogenic
response, leading to the inhibition of cell growth and, finally, cell
Figure 4. Palmitic acid stimulates PGC-1a expression and
retards high glucose-induced VSMC growth and movement.
Cultured rat VSMCs in 5.5 mM glucose were either left untreated or
stimulated with 15 mM glucose (HG) in the absence and presence of
0.4 mM palmitic acid (PA) for 48 h. PGC-1a expression was determined
by real-time RT-PCR (A) and by Western blot with PGC-1 antibody
compared with GAPDH antibody, 120 mg total proteins from VSMCs
were loaded (B). Cell growth was determined by counting the number
of cells (C). Migration distance was determined by a standard wound
healing assay (D) and transwell analysis (E). The bars represent
means6S.E.M (n=6). **P,0.01 compared with control conditions,
#P,0.001 compared with the control group.
doi:10.1371/journal.pone.0004182.g004
Figure 5. Suppression of PGC-1a abolishes the inhibitory effect
of palmitic acid on high glucose-induced VSMC growth and
movement. VSMCs were transfected with siRNA (SI) or the negative
control (N), then left stimulated with 15 mM gluoose (HG) in the
presence of 0.4 mM palmitic acid (PA) for 48 h. Cell growth was
determined by counting the number of cells (A). Migration distance
was determined by a standard wound healing assay (B) and by
transwell analysis (C). The bars represent means6S.E.M (n=6). *P,0.05,
**P,0.01, #P,0.001 compared with the N+PA+HG group.
doi:10.1371/journal.pone.0004182.g005
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coactivator for PPARc, thus regulating many physiological
processes [13–15], we hypothesized that the downregulation of
PGC-1a by glucose may play a role in an in vitro-model of VSMC
proliferation and migration induced by hyperglycemia. Our results
show that overexpression of PGC-1a by adenoviral infection
abolishes (Fig. 2), while suppression of PGC-1a amplifies (Fig. 3)
hyperglycemia-induced VSMC proliferation and migration, pro-
viding evidence for a direct role of PGC-1a in this process.
As the most prevalent saturated FFA in circulation, palmitic
acid has been shown to down-regulate PGC-1a expression in
muscle cells [26]. Our previous study found that palmitic acid had
no effect on VSMC proliferation and migration, but can markedly
increase PGC-1a expression in VSMCs [24]. The mixtures of
palmitic acid and high glucose exhibit no stimulatory effect on
VSMC proliferation and migration accompanying a persisting
induction of PGC-1a (Fig. 4). When PGC-1a is knocked down by
siRNA interference, the stimulatory effect of high glucose on
VSMC proliferation and migration was restored even in presence
of palmitic acid (Fig. 5), indicating that PGC-1a is an integration
point downstream of various nutrient-dependent signals that
regulate VSMC proliferation and migration.
It was previously shown that high glucose induces mitogenesis in
VSMCs through increasing extracellular signal-regulated kinase
(ERK) activity [3–6]. Activation of ERKs subsequently leads to the
phosphorylation and the activation of a number of downstream
targets, such as Elk-1 and Ets-1, which evoke c-Fos and MMP-9
and contribute to VSMCs growth and migration, respectively. In
the present study, high glucose markedly increased phosphorylated
ERK1/2 protein levels in VSMCs, whereas overexpression of
PGC-1a completely abolished this phosphorylation (Fig. 6).
However, little effect is observed either on VSMC proliferation
and migration or on the activity of ERK1/2 when PGC-1a was
overexpressed in the VSMCs without high glucose stimulation,
indicating that the inhibitory effect of PGC-1a on VSMC
proliferation and migration only exists in the cells which have
been exposed and responded to the mitogenic signal, instead of
quiescent VSMCs. These data suggest PGC-1a inhibits high
glucose-induced ERK activity in VSMCs, and negative regulation
of PGC-1a in VSMC proliferation and migration is achieved by
inhibiting nuclear ERK MAPK signaling. Our results confirmed
to the previous report which showed that overexpression of PGC-
1a abolished oleic acid induced ERK1/2 activity. However, it also
reported that PGC-1a expression was regulated in skeletal muscle
cells through a mechanism involving MAPK-ERK and NF-kB
activation (26), suggesting the interaction between PGC-1a
expression and ERK1/2 phosphorylation are different in various
cell types. The differences may attribute to different mechanism
involved and may relate to the regulation of specific cell function.
In VSMCs, given that PPARc has been reported to act as an
inhibitory factor upstream of the ERK MAPK pathway (9–12) and
PGC-1a is a co-activator of PPARc, the inhibitory effect of PGC-
1a on ERK activity may be mediated through the coactivation of
PPARc. The precise mechanisms of PGC-1a regulation on ERK
activity merit further study.
In summary, our results suggest that high glucose increases
VSMC proliferation and migration through PGC-1a. Experimen-
tal elevation of PGC-1a (by adenoviral overexpression or
incubation with palmitic acid) inhibits high glucose-induced
VSMC proliferation and migration. Thus, our results reveal a
novel function of PGC-1a as a regulator of VSMC proliferation
and migration, and provide a potential strategy of treatment for
diabetic atherosclerosis.
Materials and Methods
Ethics Statement
The investigation conforms to the Guide for the Care and Use of
Laboratory Animals published by the US National Institutes of
Health (NIH Publication No. 85-23, revised 1996). All animals
were treated in accordance with guidelines established by the
Nanjing University Institutional Animal Care and Use Commit-
tee.
Creating a type I diabetes rat model
Sprague-Dawley rats weighing about 180–200 g were made
diabetic by a single injection of streptozotocin (55 mg/kg
intraperitoneally) according to a previously described method
[27,28]. Blood glucose was monitored for up to 2 weeks, and only
the rats with blood glucose .16.6 mM were used for further
study. Six weeks after injection of streptozotocin, thoracic arterial
samples were obtained, and the intima and outer and inner tissue
layers were removed carefully from samples. The vessel mediae
was quickly immersed in liquid nitrogen and transferred to a
280uC freezer for later use.
Cell Culture
Primary vascular smooth muscle cells were isolated from the
thoracic aortas of 3- to4-week-old male Sprague-Dawley rats and
characterized morphologically and immunohistochemically as
described previously [29,30]. VSMCs were maintained in DMEM
(Gibco-Invitrogen, Carlsbad, USA) containing 5.5 mmol/L glu-
cose. VSMCs cultured for 4 to 8 passages were used. In glucose-
Figure 6. Increase of PGC-1a either exogenously by adenovirus
or endogenously by palmitic acid abolished high glucose
induced phosphorylation of ERK1/2 in VSMCs. VSMCs were
infected with adenovirus for 24 h, then made quiescent by serum-
starvation for 6 h, and then stimulated with HG for 4 h. Total protein
were harvested and used to detect ERK1/2 activity (A). Cultured VSMCs
in 5.5 mM glucose were made quiescent by serum-starvation for 6 h,
then cells were either left untreated or stimulated with 15 mM glucose
(HG) in the absence and presence of 0.4 mM palmitic acid (PA) for 12 h.
ERK activity were determined by Western blotting with ERK1/2 (pT202/
pY204) Phospho-Specific antibodies compared with b-tubulin antibody
and densitometric analysis of ERK1/2 activity are showed. Representa-
tive blots of three similar results are showed. #P,0.001 compared with
control.
doi:10.1371/journal.pone.0004182.g006
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DMEM medium containing 5.5, 11, 15 or 25 mmol/L glucose,
respectively. In Palmitic acid-stimulated experiments, 0.4 mmol/L
Palmitic acid (Sigma) was prepared as described previously [24].
Glucose (1000 mmol/L, dissolved in PBS then sterilized by
filtration)were also supplemented to form a final concentration
of 15 mmol/L glucose. 15 mM glucose (HG), 0.4 mmol/L
Palmitic acid (PA), HG plus PA were then applied to VSMCs
for 48 hours before RNA isolation or proliferation and migration
assays were performed.
Adenovirus Infection
Recombinant adenoviruses expressing PGC-1a GFP fusion
protein and GFP alone were kindly provided by Dr. Daniel P.
Kelly (Center for Cardiovascular Research, Washington Univer-
sity School of Medicine). VSMCs were infected with purified
adenovirus at an MOI (multiplicities of infection) of 50 to obtain
95–100% efficiency, as determined by GFP expression 24 h after
infection.
siRNA interference
Three siRNA sequences targeting different sites of rat PGC-1a
cDNA were designed and synthesized by Genesil (Wuhan, PR
China). Control sequence which could not target PGC-1a cDNA
was also included as a negative control. siRNA was transfected into
VSMCs using LipofectAmine reagent (Gibco-Invitrogen, Carlsbad,
USA) according to the manufacture’s manual. Of several sequences
tested for PGC-1a knock-down, the sequence with the best
interfering effect was selected as described previously [24].
VSMC Proliferation Assay
Cell counting analysis was performed for evaluation of the effect
of glucose on VSMC proliferation. In separate experiments,
VSMCs were seeded in 6 cm plastic dishes (1.5610
5 cells/dish)
and were allowed to grow to subconfluence, then were growth-
arrested by serum deprivation for 12 h. Cells were then divided
into several groups and were applied to different stimulation. After
48 h, cells were resuspended with 0.05% trypsin and 0.02%
EDTA, and the cell number was determined with hemocytometer.
VSMC Migration Assay
Migration of VSMCs was investigated by a standard in vitro
wound assay [30,31], and by the modified Boyden chamber assay
[30,32]. For the woundhealing assay, VSMCs were plated at an
initial density of 1610
5 cells/well on 6-well plates and were grown
to confluence to form a monolayer, then subjected to adenovirus
infection or siRNA interference according to the experiment
requirements, a plastic cell scraper was then used to make an
approximately 2.0 mm–width gap in the cell monolayer, different
stimulants were added subsequently (set as 0 time point). A
reference point was created on the bottom of the plate in the field
of the wound using direct microscopic visualization. The
measurement of the width of the gap after 48 h was subtracted
from that at 0 h to give the distance the cells migrated. The results
of the five readings from each well were averaged. Independent
stimulation experiments were repeated three times. Boyden
chamber cell migration assay was performed using transwell
chambers with fibronection-coated 8-mm-pore-size polycarbonate
membranes (BD Biosciences). Preconfluent VSMCs treated in the
same way were then suspended in DMEM–0.5% FBS to a
concentration of 4610
5 cells/mL. Different fatty acids or serum
free DMEM (0.6 mL) were added to the lower compartment. A
0.1-mL cell suspension (final concentration, 4610
4 cells/well;
diameter, 6.5 mm) was added to the upper compartment, and cells
were then incubated at 37uC (95% air–5% CO2). 6 h later, non-
migrated cells were removed with a cotton swab, and the migrated
cells were fixed with paraformal-dehyde for 30 min and stained
with crystal violet. Cell migration was quantified by blind counting
of the migrated cells on the lower surface of the membrane of 5
fields per chamber under microscope.
RNA Isolation and Analysis
Total RNA was isolated from rat arterial samples or rat VSMCs
using RNeasy kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. cDNA was synthesized and subjected
to PCR amplification with the ABI Prism 7000 sequence detection
system (Applied Biosystem, Foster City, CA) as described [24].
Sequence-specific primers and Taqman probes for real-time RT-
PCR were designed and synthesized by Shinegene Co, Shanghai.
The primer sequences used to amplify rat PGC-1a cDNA
(GenBank access number AY237127) were 59-AGGTCCCCAGG-
CAGTAGAT-39 (sense) and 59-CGTGCTCATTGGCTTCATA
(antisense), probe: 59-fam-ATGAATCAAGCCACT ACAGA-
CACC-tamra-39; primers for rat b-actin (GenBank access number
V01217) were 59-AGGGAAATCGTGCGTGAC-39 (sense) and
59-CGCTCATTGCCGATAGT G-39 (antisense), probe: 59-fam-
CTGTGCTATGTTGCCCTAGACTTC-tamra-39; Amplifica-
tion conditions were: one cycle of 95uC for 5 minutes followed by
40 cycles of 95uC for 30 seconds, 60uC for 1 minute, and final one
cycle of 72uC for 2 minutes. Relative abundance of mRNA was
determined from the CT values and was normalized to the value of
the house-keeping gene.
Western Blot Analysis
For Western blot analysis, total proteins were applied to 7.5%
SDS-PAGE gel electrophoresis for PGC-1a detection, and rabbit
polyclonal PGC-1 antibody (Santa Cruz Biotechnology, Santa
Cruz, USA) was used as primary antibody. Samples containing
50 mg total proteins were applied to 12.5% SDS-PAGE gel
electrophoresis for phosphorylated ERK1/2 detection, and
phospho-specific mouse anti-human ERK1/2 antibody (BD
Biosciences), mouse anti-human ERK antibody (BD Biosciences)
and mouse monoclonal GAPDH antibody (Santa Cruz) were used
as primary antibody.
Statistical Analysis
All results are expressed as means6SEM. Data were analyzed
using a one-way ANOVA and Student-Newman-Keuls tests for
multiple comparisons or Student’s test for unpaired data. In all
cases P#0.05 was taken as statistically significant.
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